PYX Resources: Achieving volume and diversification milestones. Watch the video here.
Like many I will be looking fora press release for EUDA, after close of NASDAQ tonight and on Monday, but it is possible that it is 30 + 15 "business days" and so the exclusivity period is not yet at an end. One would have thought that EUDA shareholders would want clarity tbf.
Valirx's well known malicious poster has posted below that Jason Pugh, who is well known to Val holders as a dishonest lunatic, says that Patrick Frankham says that there are due diligence issues causing delay. I say Jason Pugh is lying, as usual, and that the poster is trying to undermine Val, as usual. Hopefully the moderator will remove the post.
Valirx's resident malicious poster apparently thinks that a post that is almost exclusively a series of statements of facts is "ramping tosh". Goodness, how factual do facts have to be to be quality information?
PI, come on. Which holder would offer their own liquid excretion if said poster were on fire? Better ignore him or try to post in a way that makes sense if his posts are removed, and not to use his name. He craves engagement.
Valirx's notorious malicious poster is at it again, this time saying that TheoremRx don't have funds. Hopefully the moderator will remove his post soon for its misleading/false narrative. I'm reposting a great post by ironmighty, which is evidence based and alludes to them having funds.
"It's been a bit of a confusing old time, so here are the events of the last few weeks.
A group of shareholders wrote to Valirx with a set of questions. Valirx replied in the form of a ultra-bullish recorded Q&A. There was lots of info in that Q&A, but let's stick to VAL201/TheoremRX as it is the most pressing.
Suzy: “We are expecting significant updates from them before year end “
Suzy: “We have every indication we that we will be able to put out a substantial update before the end of the year”
A few days later, the empty TheoremRX website created in 2020 was finally updated with content. Just a landing page, but not for no reason.
Following that, a press release is issued stating TheoremRX plan to merge with EUDA Health, a Nasdaq listed co.
https://www.morningstar.com/news/globe-newswire/8944265/euda-health-holdings-limited-enters-into-letter-of-intent-for-proposed-merger-with-theoremrx-inc
CEO of EUDA: “We believe TheoremRx has strong access to capital and a robust pipeline of compounds.."
A statement is made that the prospectus is available online. A detailed search reveals the TMT Acquisition Corp SPAC, underwritten by Maxim Group. Maxim Group also happened to be the sole book-running manager for 8i (EUDA). TMT Acquisition prospectus also happens to contain clauses that excludes China from their business dealings (VAL removed China from the TheoremrX exclusivity earlier this year). TMT Acquisition also happens to be funded by several EUDA funders. TMT also happens to have funds of between $60m and $70m.
The merger has a 30 - 45 day window (not too many days left now). A week ago, the EUDA website is then taken offline.
IMO there is too much here for all this to be nothing.
Enjoy your day."
Minni, I think you mis-read my post. We agree that the LOI is non-binding and on what this means. It even says it's non-binding in an RNS. For the record, LOIs can be binding, but we know this one isn't.
The issue I was pointing out, is that, as far as EUDA is concerned, it is not true that TheoremRx "can" bring 201 to the merged entity, as you state. If i were EUDA's lawyers, I would insist that TheoremRx have a irrevocable right to be able to bring 201. Also, a binding contract between TheoremRx and Valirx would be carried through to the new entity - it isn't true that a binding contract must be negotiated with the new company. I'd place a (small) bet that there's a binding contract between TheoremRx and EUDA just before merger.
Valirx's notorious malicious poster is at it again. Hopefully the moderator will remove his post soon for its misleading/false narrative. I'm reposting the best post in recent times, which was by ironmighty
"It's been a bit of a confusing old time, so here are the events of the last few weeks.
A group of shareholders wrote to Valirx with a set of questions. Valirx replied in the form of a ultra-bullish recorded Q&A. There was lots of info in that Q&A, but let's stick to VAL201/TheoremRX as it is the most pressing.
Suzy: “We are expecting significant updates from them before year end “
Suzy: “We have every indication we that we will be able to put out a substantial update before the end of the year”
A few days later, the empty TheoremRX website created in 2020 was finally updated with content. Just a landing page, but not for no reason.
Following that, a press release is issued stating TheoremRX plan to merge with EUDA Health, a Nasdaq listed co.
https://www.morningstar.com/news/globe-newswire/8944265/euda-health-holdings-limited-enters-into-letter-of-intent-for-proposed-merger-with-theoremrx-inc
CEO of EUDA: “We believe TheoremRx has strong access to capital and a robust pipeline of compounds.."
A statement is made that the prospectus is available online. A detailed search reveals the TMT Acquisition Corp SPAC, underwritten by Maxim Group. Maxim Group also happened to be the sole book-running manager for 8i (EUDA). TMT Acquisition prospectus also happens to contain clauses that excludes China from their business dealings (VAL removed China from the TheoremrX exclusivity earlier this year). TMT Acquisition also happens to be funded by several EUDA funders. TMT also happens to have funds of between $60m and $70m.
The merger has a 30 - 45 day window (not too many days left now). A week ago, the EUDA website is then taken offline.
IMO there is too much here for all this to be nothing.
Enjoy your day.
On reflection Minni, this part doesn't make sense to me. I'd have thought that EUDA would want the comfort of Val and TheoremRx having a binding agreement before merging. I'd expect EUDA's lawyers to have strong advice on this.
Minni, that's a fair clarification - the LOI is non-binding. Since this and its agreements with other drug developers are what TheoremRx is bringing to the table, seems likely things will pan out okay. Agree coming to a formal agreement with the new entity might impact when Valirx is in a position to give an update.
I believe that
We've been told by RNS that "Completion of the Licence Agreement is subject to, inter alia, the successful fundraise by TheoremRx." We don't know for sure, but I'd expect there to be a time period for payment following the fundraise being deemed successful. I'd also expect the terms of the Licence to be generally confidential.
Respectfully, regarding a post below mentioning Patrick Frankham, my interpretation of his tweet is entirely different.
Valirx is a very good risk reward proposition now. Keeping to the facts seems fine to me.
Don't know why anyone would say that all the 11, 14 and 22p warrants will be exercised in the near future. Very likely some will be. Very unlikely that all will be. Anyway, after the 201 deal is over the line, cash won't be deal.
I think patient Investor is saying that Suzy could tell us what the payment term is to complete the 201 outlicence that starts when the TheoremRx derivative co is funded. It would require consent from TheoremRx or the derivative co if formed for her to give us this info. It's a reasonable request I suppose, but I doubt she'd want to bother people about this. TheoremRx 's importance is down to it having agreements in place for potential drugs, so the idea that Val will not be paid as long the merger completes seems crazy .
Hi OB, I'm known to you. I've not posted much here since Valirx's well-known malicious poster made it his day and night job to spread negativity. It ruined the BB. It's a littlr better now that his posts are being removed for their misleading/false narrative.
Every informed person understands that, if the USD2.2m doesn't arrive, there will be a placing. To my mind, it's probably irrelevant as the USD2.2m will probably arrive before even the lower deramper's assessment of when VAL's funds will run out. In any case, warnings of December are to be ignored. I believe that the latest broker note projected that Valirx would enter 2024 with £210k plus lab service fees. I haven't read this myself, but I've been reliably informed by an accountant. Yes, the money needs to come in, but it isn't as time critical as some would have readers believe.
More misleading info from the usual suspect, who is no doubt the driving force in repeatedly removing Ironmighty's well researched info. The best post in ages tbf.
We don't know exactly how to calculate the period for completing the merger. It's 30 or 45 calendar or business days from 4 October. The merged entity will want to make an announcement, probably after some well deserved Dom Perignon. Licence documents will have to be modified, not only by Valirx but by Cancer Research UK. Takes a little time. I'm sitting tight and very comfortable.
What's of interest is that it's over 100% what it was on 4 October 23, when the merger news was announced. Link to merger news here if LSE doesn't block it: https://www.nasdaq.com/press-release/euda-health-holdings-limited-enters-into-letter-of-intent-for-proposed-merger-with